Analyst Consensus ?
ConsensusHold40 ratings
Bullish2152.5%
Neutral1640.0%
Bearish37.5%
Johnson & Johnson · JNJ · FY2024 Q4 · Calendar Q1 2025
J&J Maintains 2025 Outlook Amid Pipeline Momentum and Risks
The supplied analysis supports a constructive but conditional view: J&J's oncology, immunology, neuroscience, MedTech, and pipeline activity provide growth support, while biosimilars, China exposure, product-safety review, and acquisition leverage could constrain delivery.
Reported Before market openNYSEHealthcare
$615.87B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.99
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $22.44B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-1.9%
Event window
SPY move
+0.6%
Same window
Abnormal move
-2.5%
Stock minus SPY
Volume
2.0×
Versus trailing sessions
Subsequent drift
+9.9%
Up to 20 sessions
JNJSPY benchmark
Ask FN2 about JNJ FY2024 Q4
Transcript, numbers and history already loaded
What drove JNJ's -1.9% move after FY2024 Q4 earnings?What changed in JNJ's guidance and outlook in FY2024 Q4?Give me the bull and bear case for JNJ after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current analysis emphasizes maintained 2025 guidance, continued pipeline and M&A activity, and a new execution issue around the U.S. VARIPULSE pause; the prior analysis had highlighted raised 2024 operational sales guidance and talc litigation uncertainty.
Guidance delta
Management maintained 2025 guidance at approximately 3% sales growth and approximately 9% adjusted EPS growth despite identified headwinds.
Key takeaways
- The supplied analysis reports 7% operational sales growth for 2024, excluding COVID vaccines.
- Management highlighted oncology, TREMFYA, neuroscience, MedTech innovation, and recent acquisitions as growth drivers.
- Biosimilars, China conditions, Part D redesign, the VARIPULSE pause, and acquisition-related leverage remain key watch items.
Management priorities
- Advance oncology, immunology, and neuroscience launches and pipeline programs.
- Pursue regulatory submissions and approvals for TAR-200, Impella ECP, and OTTAVA.
- Integrate Intra-Cellular Therapies while continuing to develop the MedTech portfolio.
Follow JNJ with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$255.56Current
$90Low
$229.38Average
$320High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 18, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Oct 16, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 15, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Oct 14, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 14, 2026 |
| Guggenheim | Buy | Buy | Maintain | Oct 7, 2026 |
| Citigroup | Buy | Buy | Maintain | Oct 5, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Sep 29, 2026 |
| HSBC | Buy | Buy | Maintain | Sep 10, 2026 |
| UBS | Buy | Buy | Maintain | Sep 2, 2026 |
| Raymond James | Outperform | Outperform | Maintain | Jul 16, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 13, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jul 10, 2026 |
| Stifel | Hold | Hold | Maintain | Apr 15, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Apr 15, 2026 |
| Freedom Capital Markets | Hold | Hold | Maintain | Jan 27, 2026 |
| Freedom Broker | Hold | Hold | Maintain | Jan 27, 2026 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Jan 22, 2026 |
| Bernstein | Market Perform | Market Perform | Maintain | Jan 9, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Dec 19, 2025 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Oct 16, 2024 |
| Daiwa Capital | Neutral | Outperform | Downgrade | Jul 23, 2024 |
| Atlantic Equities | Neutral | Neutral | Maintain | Aug 4, 2023 |
| Credit Suisse | Neutral | Neutral | Maintain | Jul 21, 2023 |
| Mizuho | Buy | Buy | Maintain | Jun 7, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Jan 20, 2023 |
| Independent Research | Buy | Hold | Upgrade | Jul 20, 2020 |
| Argus Research | Buy | Buy | Maintain | Mar 27, 2020 |
| BMO Capital | Outperform | Outperform | Maintain | Apr 17, 2019 |
| Argus | Buy | Buy | Maintain | May 5, 2018 |
| Stifel Nicolaus | Hold | Hold | Maintain | Apr 18, 2018 |
| Jefferies | Buy | Hold | Upgrade | Oct 11, 2017 |
| BTIG Research | Sell | Neutral | Downgrade | Jul 21, 2017 |
| BTIG | Sell | Neutral | Downgrade | Jul 21, 2017 |
| Standpoint Research | Sell | Sell | Maintain | May 20, 2016 |
| Societe Generale | Hold | Hold | Maintain | Apr 6, 2016 |
| Deutsche Bank | Buy | Buy | Maintain | Feb 4, 2016 |
| Bank of America | Neutral | Neutral | Maintain | Apr 16, 2014 |
| Davenport | Hold | Neutral | Maintain | Dec 10, 2012 |
| PiperJaffray | Neutral | Neutral | Maintain | Jul 18, 2012 |
| Piper Sandler | Neutral | Neutral | Maintain | Jul 18, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $255.56. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Wells Fargo | Larry Biegelsen | $287 | $253.28 | +12.3% | Oct 16, 2026 |
| Bernstein | Lee Hambright | $270 | $259.85 | +5.7% | Oct 15, 2026 |
| RBC Capital | Analyst unavailable | $280 | $251.68 | +9.6% | Oct 14, 2026 |
| Leerink Partners | Analyst unavailable | $272 | $251.75 | +6.4% | Oct 14, 2026 |
| Wells Fargo | Larry Biegelsen | $275 | $248.61 | +7.6% | Oct 14, 2026 |
| UBS | Analyst unavailable | $270 | $248.61 | +5.7% | Oct 14, 2026 |
| RBC Capital | Shagun Singh | $290 | $252.93 | +13.5% | Oct 6, 2026 |
| New Street | Analyst unavailable | $278 | $271.95 | +8.8% | Sep 29, 2026 |
| HSBC | Analyst unavailable | $320 | $267.08 | +25.2% | Sep 10, 2026 |
| UBS | Analyst unavailable | $320 | $271.19 | +25.2% | Sep 2, 2026 |
| Guggenheim | Analyst unavailable | $287 | $257.59 | +12.3% | Aug 6, 2026 |
| Raymond James | Analyst unavailable | $280 | $254.45 | +9.6% | Aug 3, 2026 |
| Wells Fargo | Analyst unavailable | $282 | $256.35 | +10.3% | Aug 3, 2026 |
| Argus Research | David Toung | $300 | $266.13 | +17.4% | Jul 29, 2026 |
| Johnson Rice | Ilya Zubkov | $280 | $249.76 | +9.6% | Jul 16, 2026 |
| Scotiabank | Analyst unavailable | $305 | $248.95 | +19.3% | Jul 16, 2026 |
| Raymond James | Analyst unavailable | $265 | $250.5 | +3.7% | Jul 16, 2026 |
| Johnson Rice | Analyst unavailable | $261 | $250.49 | +2.1% | Jul 16, 2026 |
| Goldman Sachs | Analyst unavailable | $282 | $247.02 | +10.3% | Jul 16, 2026 |
| Morgan Stanley | Terence Flynn | $294 | $247.02 | +15.0% | Jul 16, 2026 |
| Wells Fargo | Analyst unavailable | $272 | $247.02 | +6.4% | Jul 16, 2026 |
| Stifel Nicolaus | Rick Wise | $260 | $247.02 | +1.7% | Jul 15, 2026 |
| RBC Capital | Analyst unavailable | $287 | $257.6 | +12.3% | Jul 13, 2026 |
| Morgan Stanley | Terence Flynn | $284 | $267.24 | +11.1% | Jul 8, 2026 |
| HSBC | Analyst unavailable | $290 | $258.66 | +13.5% | Jul 6, 2026 |
| Guggenheim | Vamil Divan | $270 | $253.56 | +5.7% | Jun 26, 2026 |
| Johnson Rice | Analyst unavailable | $270 | $253.29 | +5.7% | Jun 26, 2026 |
| Leerink Partners | David Risinger | $265 | $224.26 | +3.7% | May 13, 2026 |
| Guggenheim | Analyst unavailable | $266 | $232.71 | +4.1% | Apr 20, 2026 |
| Morgan Stanley | Analyst unavailable | $283 | $239.66 | +10.7% | Apr 15, 2026 |
| RBC Capital | Analyst unavailable | $265 | $240.1 | +3.7% | Apr 15, 2026 |
| Stifel Nicolaus | Rick Wise | $250 | $240.1 | -2.2% | Apr 15, 2026 |
| Barclays | Matt Miksic | $255 | $240.1 | -0.2% | Apr 15, 2026 |
| Morgan Stanley | Analyst unavailable | $267 | $239.5 | +4.5% | Apr 10, 2026 |
| Morgan Stanley | Analyst unavailable | $253 | $237.19 | -1.0% | Mar 18, 2026 |
| RBC Capital | Analyst unavailable | $255 | $233.35 | -0.2% | Feb 3, 2026 |
| Morgan Stanley | Terrance Flynn | $262 | $224.44 | +2.5% | Jan 28, 2026 |
| Loop Capital Markets | Ilya Zubkov | $220 | $225.16 | -13.9% | Jan 27, 2026 |
| Guggenheim | Vamil Divan | $240 | $218.49 | -6.1% | Jan 23, 2026 |
| Scotiabank | Analyst unavailable | $265 | $220.18 | +3.7% | Jan 22, 2026 |
| Morgan Stanley | Terence Flynn | $200 | $220.37 | -21.7% | Jan 22, 2026 |
| Stifel Nicolaus | Rick Wise | $220 | $218.01 | -13.9% | Jan 22, 2026 |
| Goldman Sachs | Asad Haider | $250 | $218.01 | -2.2% | Jan 22, 2026 |
| Wells Fargo | Analyst unavailable | $240 | $218.01 | -6.1% | Jan 22, 2026 |
| Bernstein | Lee Hambright | $208 | $205.75 | -18.6% | Jan 9, 2026 |
| Barclays | Matt Miksic | $217 | $207.56 | -15.1% | Dec 30, 2025 |
| Goldman Sachs | Asad Haider | $240 | $210.33 | -6.1% | Dec 18, 2025 |
| RBC Capital | Analyst unavailable | $240 | $209.08 | -6.1% | Dec 17, 2025 |
| Morgan Stanley | Analyst unavailable | $197 | $210.6 | -22.9% | Dec 12, 2025 |
| RBC Capital | Analyst unavailable | $230 | $206.54 | -10.0% | Dec 11, 2025 |
| HSBC | Analyst unavailable | $240 | $199.96 | -6.1% | Dec 10, 2025 |
| Guggenheim | Analyst unavailable | $227 | $202.48 | -11.2% | Dec 5, 2025 |
| Barclays | Analyst unavailable | $197 | $205.34 | -22.9% | Dec 2, 2025 |
| Johnson Rice | Ilya Zubkov | $190 | $193.18 | -25.7% | Oct 22, 2025 |
| Loop Capital Markets | Ilya Zubkov | $190 | $193.18 | -25.7% | Oct 22, 2025 |
| Argus Research | David Toung | $210 | $191.19 | -17.8% | Oct 15, 2025 |
| Raymond James | Analyst unavailable | $209 | $190.85 | -18.2% | Oct 15, 2025 |
| Morgan Stanley | Terence Flynn | $190 | $190.85 | -25.7% | Oct 15, 2025 |
| Stifel Nicolaus | Analyst unavailable | $190 | $190.85 | -25.7% | Oct 15, 2025 |
| UBS | Analyst unavailable | $214 | $187.22 | -16.3% | Oct 14, 2025 |
| RBC Capital | Shagun Singh | $209 | $191.3 | -18.2% | Oct 10, 2025 |
| Bernstein | Analyst unavailable | $193 | $188.64 | -24.5% | Oct 6, 2025 |
| UBS | Analyst unavailable | $198 | $185.98 | -22.5% | Oct 3, 2025 |
| Wells Fargo | Larry Biegelsen | $212 | $185.98 | -17.0% | Oct 3, 2025 |
| Raymond James | Jayson Bedford | $162 | $154.36 | -36.6% | Apr 14, 2025 |
| Guggenheim | Vamil Divan | $166 | $151.87 | -35.0% | Feb 3, 2025 |
| Goldman Sachs | Chris Shibutani | $159 | $164.28 | -37.8% | Oct 16, 2024 |
| Morgan Stanley | Terence Flynn | $175 | $164.1 | -31.5% | Oct 16, 2024 |
| RBC Capital | Shagun Singh | $181 | $164.1 | -29.2% | Oct 16, 2024 |
| Citigroup | Joanne Wuensch | $185 | $164.1 | -27.6% | Oct 16, 2024 |
| Wells Fargo | Larry Biegelsen | $166 | $164.1 | -35.0% | Oct 15, 2024 |
| Stifel Nicolaus | Rick Wise | $170 | $164.1 | -33.5% | Oct 15, 2024 |
| Citigroup | Joanna Wuensch | $180 | $163.77 | -29.6% | Oct 15, 2024 |
| Cantor Fitzgerald | Louise Chen | $215 | $161.6 | -15.9% | Oct 14, 2024 |
| Johnson Rice | Narumi Nakagiri | $150 | $154.24 | -41.3% | Jul 23, 2024 |
| Stifel Nicolaus | Rick Wise | $160 | $157.16 | -37.4% | Jul 17, 2024 |
| Johnson Rice | Chris Shibutani | $160 | $144.44 | -37.4% | May 30, 2024 |
| Goldman Sachs | Chris Shibutani | $160 | $144.42 | -37.4% | May 30, 2024 |
| UBS | Danielle Antalffy | $180 | $152.34 | -29.6% | May 22, 2024 |
| Johnson Rice | Morten Herholdt | $170 | $145.08 | -33.5% | Apr 18, 2024 |
| Johnson Rice | Louise Chen | $215 | $144.32 | -15.9% | Apr 17, 2024 |
| RBC Capital | Shagun Singh | $175 | $144.45 | -31.5% | Apr 17, 2024 |
| Stifel Nicolaus | Rick Wise | $155 | $144.45 | -39.3% | Apr 16, 2024 |
| Raymond James | Jayson Bedford | $175 | $155.77 | -31.5% | Mar 27, 2024 |
| Raymond James | Jayson Bedford | $110 | $156.35 | -57.0% | Dec 28, 2023 |
| Johnson Rice | Shagun Singh | $178 | $157.24 | -30.3% | Oct 5, 2023 |
| Johnson Rice | Trung Huynh | $175 | $170.45 | -31.5% | Jul 21, 2023 |
| Raymond James | John Ransom | $90 | $156.6 | -64.8% | May 24, 2023 |
| Citigroup | Analyst unavailable | $205 | $176.17 | -19.8% | Dec 12, 2022 |
| Morgan Stanley | Analyst unavailable | $176 | $178.79 | -31.1% | Dec 6, 2022 |
| Morgan Stanley | Analyst unavailable | $178 | $178.49 | -30.3% | Dec 1, 2022 |
| UBS | Analyst unavailable | $180 | $170.71 | -29.6% | Jul 21, 2022 |
| Atlantic Equities | Steve Chesney | $165 | $170.71 | -35.4% | Jul 20, 2022 |
| Leerink Partners | Analyst unavailable | $194 | $170.86 | -24.1% | Jul 20, 2022 |
| Raymond James | Analyst unavailable | $192 | $171.69 | -24.9% | Jul 20, 2022 |
| Citigroup | Analyst unavailable | $201 | $171.69 | -21.3% | Jul 20, 2022 |
| Morgan Stanley | Analyst unavailable | $174 | $178.5 | -31.9% | Jul 8, 2022 |
| Citigroup | Analyst unavailable | $210 | $183.51 | -17.8% | Apr 20, 2022 |
| Raymond James | Analyst unavailable | $196 | $183.46 | -23.3% | Apr 20, 2022 |
| Credit Suisse | Analyst unavailable | $205 | $182.64 | -19.8% | Apr 20, 2022 |
| Raymond James | Jayson Bedford | $195 | $177.66 | -23.7% | Apr 18, 2022 |
| Morgan Stanley | Matthew Harrison | $173 | $179.84 | -32.3% | Apr 11, 2022 |
| Societe Generale | Florent Cespedes | $177 | $171.79 | -30.7% | Jan 28, 2022 |
| Goldman Sachs | Chris Shibutani | $163 | $168.38 | -36.2% | Jan 26, 2022 |
| Credit Suisse | Matt Miksic | $200 | $170.46 | -21.7% | Dec 29, 2021 |
| UBS | Kevin Caliendo | $183 | $166.8 | -28.4% | Jul 22, 2021 |
| Argus Research | David Toung | $190 | $166.8 | -25.7% | Jul 22, 2021 |
Track every rating change on JNJ the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationJohnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Historical context
All JNJ earningsLatest beats and misses
Who reports nextBeat on EPS
Get the JNJ recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-08T00:01:14.930234+00:00
- Polygon adjusted daily market bars · 2026-10-18T11:50:41.889635+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-18T11:50:41.886803+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-18. For educational purposes only; not investment advice.